Effectiveness and safety of interleukin-2 plus cisplatin for treating malignant pleural effusion:a meta analysis
10.3969/j.issn.1671-8348.2017.01.020
- VernacularTitle:白细胞介素2联合顺铂治疗恶性胸腔积液有效性及安全性的Meta分析
- Author:
Yongping SUN
;
Chengqiong WANG
;
Ling CHEN
;
Nana LI
;
Xinsheng YAO
;
Zheng XIAO
- Keywords:
interleukin-2;
cisplatin;
pleural effusion,malignant;
meta analysis
- From:
Chongqing Medicine
2017;46(1):84-89,93
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the effectiveness and safety of interleukin-2 plus cisplatin for treating ma-lignant pleural effusion(MPE)to provide a basis for clinical treatment strategy.Methods CBM,CNKI,VIP,Wanfang,Pubmed, Embase,Cochrane library clinical trial registration database were systematically retrieved.The randomized controlled trial(RCT) quality assessment criteria of Cochrane collaboration network was adopted for including the study quality.The data were extracted by meta analysis.Results (1)Thirty-four RCT involving 2 037 MPE patients were included,the quality of included RCT was ordi-nary;(2)compared with simple cisplatin,the merged RR values and their 95%CI of meta-analysis for ORR,fever,were 1.45 (1.36-1.54),2.37 (1.53 -3.66),respectively,the differences between the two groups were statistically significant(P <0.05 ). The merged RR values and their 95%CI of meta-analysis for leukopenia,myelosuppression and thoracalgia were 0.81 (0.61 -1.07),0.83(0.62-1.11)and 1.04(0.84-1.29)respectively,the differences between two groups were not statistically significant (P >0.05).Conclusion This study indicates that IL-2 plus cisplatin can significantly improve the clinical curative effect in the pa-tients with MPE,but has the adverse reactions of fever,etc.and the quality of included RCT is general.
